share_log

424B3: Prospectus

424B3: Prospectus

424B3：募資說明書
美股SEC公告 ·  2024/11/22 15:38

Moomoo AI 已提取核心訊息

On October 31, 2024, NeuroSense Therapeutics entered into a Standby Equity Purchase Agreement with YA II PN, LTD., allowing the sale of up to $30 million in ordinary shares over 36 months. NeuroSense will not receive proceeds from the sale of shares by the Selling Shareholder but may receive up to $30 million from sales to YA under the agreement.The agreement includes the issuance of 224,697 Commitment Shares to YA as consideration. An additional 9,775,303 Advance Shares may be sold to YA at 97% of the lowest VWAP during a pricing period. The shares will be sold at NeuroSense's discretion, subject to market conditions and other factors.NeuroSense's ordinary shares are traded on Nasdaq under the symbol "NRSN". The company is an emerging growth company and a foreign private issuer, benefiting from reduced disclosure requirements. The proceeds will support the development of pipeline products and general corporate purposes.
On October 31, 2024, NeuroSense Therapeutics entered into a Standby Equity Purchase Agreement with YA II PN, LTD., allowing the sale of up to $30 million in ordinary shares over 36 months. NeuroSense will not receive proceeds from the sale of shares by the Selling Shareholder but may receive up to $30 million from sales to YA under the agreement.The agreement includes the issuance of 224,697 Commitment Shares to YA as consideration. An additional 9,775,303 Advance Shares may be sold to YA at 97% of the lowest VWAP during a pricing period. The shares will be sold at NeuroSense's discretion, subject to market conditions and other factors.NeuroSense's ordinary shares are traded on Nasdaq under the symbol "NRSN". The company is an emerging growth company and a foreign private issuer, benefiting from reduced disclosure requirements. The proceeds will support the development of pipeline products and general corporate purposes.
2024年10月31日，NeuroSense Therapeutics與YA II PN, LTD. 簽訂了備用股權購買協議，允許在36個月內出售高達3000萬美元的普通股。NeuroSense不會獲得出售股東出售股票的收益，但根據該協議，向YA的出售可能獲得高達3000萬美元的收益。該協議包括向YA發行224,697股承諾股作爲對價。在定價期內，還可能以最低VWAP的97％向YA出售另外9,775,303股高級股票。這些股票將由NeuroSense自行決定出售，但須視市場狀況和其他因素而定。NeuroSense的普通股在納斯達克上市，股票代碼爲 「NRSN」。該公司是一家新興成長型公司和外國私人發行人，受益於披露要求的降低。所得款項將用於支持管道產品的開發和一般公司用途。
2024年10月31日，NeuroSense Therapeutics與YA II PN, LTD. 簽訂了備用股權購買協議，允許在36個月內出售高達3000萬美元的普通股。NeuroSense不會獲得出售股東出售股票的收益，但根據該協議，向YA的出售可能獲得高達3000萬美元的收益。該協議包括向YA發行224,697股承諾股作爲對價。在定價期內，還可能以最低VWAP的97％向YA出售另外9,775,303股高級股票。這些股票將由NeuroSense自行決定出售，但須視市場狀況和其他因素而定。NeuroSense的普通股在納斯達克上市，股票代碼爲 「NRSN」。該公司是一家新興成長型公司和外國私人發行人，受益於披露要求的降低。所得款項將用於支持管道產品的開發和一般公司用途。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Lexeo Therapeutics
    LXEO
    -- 4.090
    Polyrizon
    PLRZ
    -- 0.750
    Dominari Holdings
    DOMH
    -- 5.490
    Tonix Pharmaceuticals
    TNXP
    -- 30.5100
    Codexis
    CDXS
    -- 3.070
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點